Mirraza Shinjuku Tsurukame Clinic, Tokyo, Japan.
Department of Endocrinology and Metabolism, Tokyo Metropolitan Okubo Hospital, Tokyo, Japan.
Front Endocrinol (Lausanne). 2024 May 8;15:1392280. doi: 10.3389/fendo.2024.1392280. eCollection 2024.
The incidence of steatotic liver disease has increased in recent years. Thus, steatotic liver disease is a major public health issue in Japan. This study investigated the association between weight reduction and the remission of metabolic dysfunction-associated steatotic liver disease (MASLD)/Metabolic and alcohol related/associated liver disease (MetALD) in Japanese individuals undergoing health checkups.
This retrospective observational study included 8,707 Japanese patients with MASLD/MetALD who underwent health checkups from May 2015 to March 2023. The participants were monitored for its remission at their subsequent visit. MASLD was diagnosed on abdominal ultrasonography and based on the presence of at least one of five metabolic abnormalities. The impact of body mass index (BMI) reduction on MASLD/MetALD remission was assessed via logistic regression analysis and using receiver operating characteristic curves.
Logistic regression analysis revealed that weight loss was significantly associated with MASLD/MetALD remission. Other factors including exercise habits and reduced alcohol consumption were significant predictors of MASLD/MetALD remission in the overall cohort and in male patients. The optimal BMI reduction cutoff values for MASLD/MetALD remission were 0.9 kg/m and 4.0% decrease in the overall cohort, 0.85 kg/m and 3.9% decrease in males, and 1.2 kg/m and 4.5% decrease in females. In participants with a BMI of 23 kg/m, the cutoff values were 0.75 kg/m and 2.7% BMI reduction.
Weight reduction plays an important role in both MASLD and MetALD remission among Japanese individuals. That is, targeting specific BMI reduction is effective. This underscores the importance of targeted weight management strategies in preventing and managing MASLD/MetALD in the Japanese population.
近年来，脂肪性肝病的发病率有所增加。因此，脂肪性肝病是日本的一个主要公共卫生问题。本研究调查了在接受健康检查的日本人中，体重减轻与代谢相关脂肪性肝病（MASLD）/代谢和酒精相关/相关肝病（MetALD）缓解之间的关系。
本回顾性观察性研究纳入了 2015 年 5 月至 2023 年 3 月期间进行健康检查的 8707 例 MASLD/MetALD 日本患者。在随后的就诊中对患者的缓解情况进行监测。MASLD 通过腹部超声检查和至少存在五种代谢异常中的一种来诊断。通过逻辑回归分析和接受者操作特征曲线评估体重指数（BMI）降低对 MASLD/MetALD 缓解的影响。
逻辑回归分析显示，体重减轻与 MASLD/MetALD 缓解显著相关。其他因素，包括运动习惯和减少饮酒，是总体队列和男性患者中 MASLD/MetALD 缓解的显著预测因素。MASLD/MetALD 缓解的最佳 BMI 降低截止值为总体队列中的 0.9kg/m 和 BMI 降低 4.0%，男性中的 0.85kg/m 和 BMI 降低 3.9%，女性中的 1.2kg/m 和 BMI 降低 4.5%。在 BMI 为 23kg/m 的参与者中，截止值为 0.75kg/m 和 BMI 降低 2.7%。
体重减轻在日本人 MASLD 和 MetALD 缓解中都起着重要作用。也就是说，针对特定的 BMI 降低是有效的。这强调了在日本人群中针对特定 BMI 管理策略预防和管理 MASLD/MetALD 的重要性。
